152P - Palliative treatment of refractory metastatic colorectal cancer using Regorafenib : Macau experience. (152P)

Date 18 November 2017
Event ESMO Asia 2017 Congress
Session Poster lunch
Topics Anti-Cancer Agents & Biologic Therapy
Palliative Care
Colon Cancer
Rectal Cancer
Gastrointestinal Cancers
Palliative and Supportive Care
Presenter Xianghong Peng
Citation Annals of Oncology (2017) 28 (suppl_10): x42-x56. 10.1093/annonc/mdx659
Authors X. Peng, Y. Lin, Y. Wang, C. Hui, C. Lam
  • Medical Oncology, CHCSJ Hospital, macau - Macau/MO

Abstract

Background

Regorafenib has been applied in patients with metastatic colorectal cancer (mCRC) as 3rd/4th line treatment. However, there are limited data about the efficacy, dose modification and adverse effects on Asian patients, and no data on this drug in Macau. Here, we provided above clinical information in patients with mCRC in Macau clinical practice.

Methods

We retrospectively reviewed mCRC patients treated with regorafenib monotherapy in Centro Hospitalar Conde de São Januário (Macau), between May 2014 and June 2017. All patients had previously treated by palliative chemotherapy regimens using fluorouracil, irinotecan, and oxaliplatin with biologic agents such as cetuximab or bevacizumab.

Results

Thirty-six patients received regorafenib monotherapy (median age, 58 years (32-92 yrs); male:femal e ratio, 19:17; Eastern Cooperative Oncology Group performance status [0:1], 22:14; colon:rectum, 30:6). Fifteen patients (41%) initially received 160mg/day, while the reforafenib had to be modified to 120 or 80 mg/day in another 21 patients (59%). The median duration of treatment was 4.5 months (range, 0.75–16.0 months). The disease control rate was 47.2% (17/36). The most common adverse events of regorafenib were hand-foot skin reaction (69.4%), fatigue (41.6%), liver function test abnormalities (38.9%), mucositis (36.1%), rash (36.1%), diarrhea (33.3%), hyperbilirubinemia (27.7%), hypertension (16.6%).There was no treatment-related death. Grade 3 or 4 treatment-related hand–foot skin reaction occurred in 11 patients (30.5%), which was the main reason for modifying the dose of the ragorafenib. The regorafenib-related hyperbilirubinemia (grade 3 and 4) may be associated with worsened prognosis significantly when compared to that of patients with normal bilirubinemia.

Conclusions

Regorafenib may be used as 3rd/4th line palliative chemotherapy in patients with refractory CRC with promising efficacy in Macau, and the related side effects could be manageable.

Clinical trial identification

N/A

Legal entity responsible for the study

N/A.

Funding

None

Disclosure

All authors have declared no conflicts of interest.